Haloperidol Teva (Haloperidol)

Haloperidol Teva is indicated for the management of several psychiatric disorders where dopamine blockade is therapeutic.

• Treatment of schizophrenia, including acute exacerbations.
• Control of acute psychotic episodes unrelated to schizophrenia.
• Management of manic episodes associated with bipolar disorder.
• Reduction of motor and vocal tics in Tourette syndrome.
• Adjunctive therapy for severe agitation in hospitalized patients.
• Short‑term use for severe behavioral disturbances when rapid tranquilization is required.

Haloperidol Teva may cause a range of side effects that vary in frequency and severity.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Blurred vision or other visual disturbances.
• Weight gain or changes in appetite.

Serious

• Neuroleptic malignant syndrome, a potentially life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Severe hypotension or cardiovascular effects.
• Elevated prolactin levels leading to hormonal disturbances.
• Seizures in predisposed individuals.
• Severe allergic reactions, including anaphylaxis.

Before initiating Haloperidol Teva, clinicians should evaluate patient history and monitor for specific risks.

• Assess for a history of cardiovascular disease, arrhythmias, or prolonged QT interval.
• Evaluate for pre‑existing movement disorders or Parkinsonian symptoms.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be needed.
• Monitor for signs of neuroleptic malignant syndrome, especially during dose escalation.
• Consider pregnancy and lactation status; discuss potential risks with the patient.
• Regularly review concomitant medications that may prolong the QT interval.
• Educate patients about the importance of reporting new or worsening side effects promptly.

Haloperidol Teva can interact with several drug classes, affecting safety and efficacy.

Avoid

• Other dopamine antagonists or antipsychotics that increase the risk of extrapyramidal symptoms.
• Medications known to prolong the QT interval, such as certain antiarrhythmics, macrolide antibiotics, and some antipsychotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma levels.

Use with caution

• CYP3A4 inducers (e.g., rifampin, carbamazepine) that could reduce therapeutic effect.
• CNS depressants, including benzodiazepines and opioids, which may enhance sedation.
• Anticholinergic agents that can mask extrapyramidal side effects.
• Lithium, as combined use may increase the risk of neurotoxicity.
• Alcohol, which can potentiate central nervous system effects.